---
title: PHC Corporation’s Biomedical Division wins 2025 R&D 100 award for LiCellMo Live Cell Metabolic Pathway Analyzer
description: PHCbi’s live cell metabolic pathway analyzer, LiCellMo® has been recognized with an R&D100 Award.
image: https://news.lifesciencenewswire.com/hubfs/RD100-Web-Thumbnail-305x305%20(1).jpg
---

[![Life Science Newswire 2](https://news.lifesciencenewswire.com/hs-fs/hubfs/Life%20Science%20Newswire%202.png?width=203&height=60&name=Life%20Science%20Newswire%202.png "Life Science Newswire 2")](https://lifesciencenewswire.com/)

- [Newsroom](https://news.lifesciencenewswire.com/newsroom)
- [Back to the main site](https://lifesciencenewswire.com/)

![LSNewswire-main-header-banner-v2-1](https://news.lifesciencenewswire.com/hubfs/LSNewswire-main-header-banner-v2-1.jpg "LSNewswire-main-header-banner-v2-1")

# Newsroom

#### Categories ![Arrow](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/sidebar.svg "Arrow")

#### Subscribe![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/subscribe-rss-button.svg)

![](https://cdn2.hubspot.net/hubfs/3842749/ps4-Pack/close-button.svg)

### Choose a Category

- [Agriculture (1)](https://news.lifesciencenewswire.com/newsroom/tag/agriculture)
- [Analytical Chemistry (42)](https://news.lifesciencenewswire.com/newsroom/tag/analytical-chemistry)
- [Biomanufacturing (34)](https://news.lifesciencenewswire.com/newsroom/tag/biomanufacturing)
- [biopharma (20)](https://news.lifesciencenewswire.com/newsroom/tag/biopharma)
- [Bioprocessing (15)](https://news.lifesciencenewswire.com/newsroom/tag/bioprocessing)
- [Biotechnology (244)](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology)
- [Cell Culture (9)](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture)
- [Clinical Diagnostics (36)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-diagnostics)
- [clinical research (6)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research)
- [Clinical Research & Trials (108)](https://news.lifesciencenewswire.com/newsroom/tag/clinical-research-trials)
- [Computing & Technology (62)](https://news.lifesciencenewswire.com/newsroom/tag/computing-it)
- [Corporate, Finance & Investor (283)](https://news.lifesciencenewswire.com/newsroom/tag/corporate-finance-investor)
- [COVID-19 (86)](https://news.lifesciencenewswire.com/newsroom/tag/covid-19)
- [Diagnostics & Hospital Laboratory (35)](https://news.lifesciencenewswire.com/newsroom/tag/diagnostics-hospital-laboratory)
- [Drug Discovery & Development (147)](https://news.lifesciencenewswire.com/newsroom/tag/drug-discovery-development)
- [Energy & Environment (15)](https://news.lifesciencenewswire.com/newsroom/tag/energy-environment)
- [excipients (1)](https://news.lifesciencenewswire.com/newsroom/tag/excipients)
- [Food & Beverage (8)](https://news.lifesciencenewswire.com/newsroom/tag/food-beverage)
- [General Chemistry (7)](https://news.lifesciencenewswire.com/newsroom/tag/general-chemistry)
- [General Laboratory (55)](https://news.lifesciencenewswire.com/newsroom/tag/general-laboratory)
- [General Science (5)](https://news.lifesciencenewswire.com/newsroom/tag/general-science)
- [Healthcare (132)](https://news.lifesciencenewswire.com/newsroom/tag/healthcare)
- [Hospital Management (6)](https://news.lifesciencenewswire.com/newsroom/tag/hospital-management)
- [Life Science (26)](https://news.lifesciencenewswire.com/newsroom/tag/life-science)
- [Manufacturing (2)](https://news.lifesciencenewswire.com/newsroom/tag/manufacturing)
- [Materials Science (2)](https://news.lifesciencenewswire.com/newsroom/tag/materials-science)
- [Medical Devices & Technology (25)](https://news.lifesciencenewswire.com/newsroom/tag/medical-devices-technology)
- [Microbiology & Infection Control (18)](https://news.lifesciencenewswire.com/newsroom/tag/microbiology-infection-control)
- [Microscopy & Imaging (47)](https://news.lifesciencenewswire.com/newsroom/tag/microscopy-imaging)
- [Nanotech (2)](https://news.lifesciencenewswire.com/newsroom/tag/nanotech)
- [Omics & Genetics (86)](https://news.lifesciencenewswire.com/newsroom/tag/omics-genetics)
- [Pathology (5)](https://news.lifesciencenewswire.com/newsroom/tag/pathology)
- [Pharma (114)](https://news.lifesciencenewswire.com/newsroom/tag/pharma)
- [Pharmacy (4)](https://news.lifesciencenewswire.com/newsroom/tag/pharmacy)
- [Research (47)](https://news.lifesciencenewswire.com/newsroom/tag/research)
- [Veterinary (5)](https://news.lifesciencenewswire.com/newsroom/tag/veterinary)
- [Water (8)](https://news.lifesciencenewswire.com/newsroom/tag/water)

See all

### Subscribe to Email Updates

- ##### SHARE
- <https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fnews.lifesciencenewswire.com%2Fnewsroom%2Fphc-corporations-biomedical-division-wins-2025-rd-100-award-for-licellmo-live-cell-metabolic-pathway-analyzer>
- <https://www.twitter.com/share?url=https%3A%2F%2Fnews.lifesciencenewswire.com%2Fnewsroom%2Fphc-corporations-biomedical-division-wins-2025-rd-100-award-for-licellmo-live-cell-metabolic-pathway-analyzer>
- <http://www.linkedin.com/shareArticle?mini=true&url=https://news.lifesciencenewswire.com/newsroom/phc-corporations-biomedical-division-wins-2025-rd-100-award-for-licellmo-live-cell-metabolic-pathway-analyzer>

# [PHC Corporation’s Biomedical Division wins 2025 R&D 100 award for LiCellMo Live Cell Metabolic Pathway Analyzer](https://news.lifesciencenewswire.com/newsroom/phc-corporations-biomedical-division-wins-2025-rd-100-award-for-licellmo-live-cell-metabolic-pathway-analyzer)

 September 8, 2025

![RD100-Web-Thumbnail-305x305 (1)](https://news.lifesciencenewswire.com/hs-fs/hubfs/RD100-Web-Thumbnail-305x305%20(1).jpg?width=305&height=305&name=RD100-Web-Thumbnail-305x305%20(1).jpg)The Biomedical Division of [PHC Corporation](https://www.phchd.com/) (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Nobuaki Nakamura), has been honored with a 2025 “R&D 100 Award” from R&D World[1](https://www.rdworldonline.com/revealing-the-2025-rd-100-awards-winners/) for its innovative live cell metabolic pathway analyzer, LiCellMo.

LiCellMo was launched for research use in Japan in September 2024, followed by availability for research use in the United States, UK, EU, China and other Asian select geographies in October 2024[2](https://www.phchd.com/global/phc/news/2024/0904) . The device provides continuous real time data on key cellular metabolic pathways3, offering researchers unprecedented visibility into dynamic changes in cell states. This enables more informed decision-making and supports potential breakthroughs and therapeutic development.

Designed to enhance understanding of cellular metabolic mechanisms, LiCellMo also improves reproducibility and quality of cell cultures—critical for developing manufacturing processes for cell and gene therapy products.

The R&D 100 Awards, established in 1963, recognize the 100 most revolutionary technologies of the past year. It is the only science and technology competition that honors new commercially available products, technologies and materials for their technological significance.

In cell and gene therapy (CGT) research, accurately assessing cell states and optimizing culture environments is essential. LiCellMo addresses this need by enabling real-time visualization of metabolic changes in cell cultures. Unlike conventional methods that rely on periodic sampling — risking contamination and missing key transitions — LiCellMo continuously monitors glucose and lactate levels minute by minute. It integrates seamlessly into existing compatible CO2 incubators without altering culture environment, offering a flexible and low-disruption solution to common cell culture challenges.

LiCellMo incorporates proprietary in-line monitoring technology4 originally developed by PHC Corporation’s *In-Vitro* Diagnostics (IVD) Division for blood glucose sensors. PHC Corporation is a subsidiary of PHC Holdings Corporation (TSE: 6523), a member of PHC Group.

Chikara Takauo, Director of PHC Corporation and Head of the Biomedical Division, said, "We are deeply honored that LiCellMo has been recognized with an R&D 100 Award. This innovation empowers researchers with new insights into cell metabolism, particularly in cancer immunology and stem cell research, and supports the advancement of manufacturing processes for next generation therapies. "

 

References

1. [https://www.rdworldonline.com/revealing-the-2025-rd-100-awards-winners/](https://www.rdworldonline.com/revealing-the-2025-rd-100-awards-winners/)
2. [https://www.phchd.com/global/phc/news/2024/0904](https://www.phchd.com/global/phc/news/2024/0904)
3. A series of biochemical reactions within cultured cells that produce the energy required for cellular functions and survival.
4. A technology that enables continuous measurement of cellular metabolites in culture medium without the need for sampling, achieved by maintaining constant immersion in the medium.

### About the Biomedical Division of PHC Corporation

Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TSE 6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its PHCbi-branded laboratory and equipment and services including CO2 incubators and ultra-low temperature freezers.  
[www.phchd.com/global/phc](https://www.phchd.com/global/phc)

 

### About PHC Holdings Corporation (PHC Group)

PHC Holdings Corporation (TSE 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group’s consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries.  
[www.phchd.com](https://www.phchd.com/)

 Categories: [Biotechnology](https://news.lifesciencenewswire.com/newsroom/tag/biotechnology), [Cell Culture](https://news.lifesciencenewswire.com/newsroom/tag/cell-culture)

##### Browse more news

## Recent releases

<https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai>

#### [Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Enginee...](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai)

 July 6, 2026

Strengthens ECI’s AI & Digital Transformation capabilities to help clients develop the next generation of software-enabled medical technologies En...

##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/enhanced-compliance-inc.-eci-appoints-taranjit-s.-samra-as-head-of-medical-device-software-engineering-cybersecurity-and-ai)

<https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale>

#### [Alithea Genomics Launches Early Access Program for MERCURIUS™ 1536 DRUG-seq, Bringing Transcriptomic...](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale)

 June 16, 2026

New ultra-high-throughput kit enables discovery teams to generate transcriptome-wide compound-response data directly from 1536-well plates Alithea Gen...

##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/alithea-genomics-launches-early-access-program-for-mercurius-1536-drug-seq-bringing-transcriptomics-to-compound-screening-scale)

<https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer>

#### [Arscience Biotherapeutics Appoints Gustavo Mahler as Chief Executive Officer](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer)

 June 16, 2026

Seasoned Biopharmaceutical Leader and Board Director Steps Up to Lead the Company’s Next Phase of Growth in Customized Interleukin Therapies ARScience...

##### [READ MORE](https://news.lifesciencenewswire.com/newsroom/arscience-biotherapeutics-appoints-gustavo-mahler-as-chief-executive-officer)

![LS-Newswire-reverse](https://news.lifesciencenewswire.com/hs-fs/hubfs/raw_assets/public/LifeScienceNewswire_June2020/images/LS-Newswire-reverse.png?width=150&name=LS-Newswire-reverse.png "LS-Newswire-reverse")

Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225 

#### Useful information

- [Cookie and privacy policy](https://lifesciencenewswire.com/cookie-privacy-policy/)
- [Website terms and conditions](https://lifesciencenewswire.com/terms-and-conditions)
- [Promotion terms and conditions](https://lifesciencenewswire.com/promotion_terms/)